CN116570542A - Composition with effects of relaxing, relieving, resisting and relieving itching and application thereof - Google Patents
Composition with effects of relaxing, relieving, resisting and relieving itching and application thereof Download PDFInfo
- Publication number
- CN116570542A CN116570542A CN202310606411.4A CN202310606411A CN116570542A CN 116570542 A CN116570542 A CN 116570542A CN 202310606411 A CN202310606411 A CN 202310606411A CN 116570542 A CN116570542 A CN 116570542A
- Authority
- CN
- China
- Prior art keywords
- composition
- soothing
- skin
- extract
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 73
- 230000000694 effects Effects 0.000 title claims abstract description 41
- 230000002040 relaxant effect Effects 0.000 title claims abstract description 16
- 208000003251 Pruritus Diseases 0.000 title abstract description 34
- 230000007803 itching Effects 0.000 title abstract description 24
- 239000000284 extract Substances 0.000 claims abstract description 38
- 230000003266 anti-allergic effect Effects 0.000 claims abstract description 26
- 239000002537 cosmetic Substances 0.000 claims abstract description 26
- 230000001139 anti-pruritic effect Effects 0.000 claims abstract description 25
- 239000003906 humectant Substances 0.000 claims abstract description 24
- 229940107491 kava root Drugs 0.000 claims abstract description 20
- 229940114496 olive leaf extract Drugs 0.000 claims abstract description 20
- 244000223977 Tuber melanosporum Species 0.000 claims abstract description 17
- 235000002777 Tuber melanosporum Nutrition 0.000 claims abstract description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 16
- -1 glycerol glucoside Chemical class 0.000 claims abstract description 16
- 239000003908 antipruritic agent Substances 0.000 claims abstract description 10
- 229930182478 glucoside Natural products 0.000 claims abstract description 5
- 239000007921 spray Substances 0.000 claims description 48
- 239000006071 cream Substances 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 229930182470 glycoside Natural products 0.000 claims description 7
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 abstract description 30
- 230000003020 moisturizing effect Effects 0.000 abstract description 23
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 14
- 208000026935 allergic disease Diseases 0.000 abstract description 10
- 230000007815 allergy Effects 0.000 abstract description 10
- 206010070834 Sensitisation Diseases 0.000 abstract description 9
- 230000035807 sensation Effects 0.000 abstract description 7
- 230000002195 synergetic effect Effects 0.000 abstract description 7
- 206010006784 Burning sensation Diseases 0.000 abstract description 3
- 229920005862 polyol Polymers 0.000 abstract description 3
- 150000003077 polyols Chemical class 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 103
- 239000000686 essence Substances 0.000 description 72
- 230000000052 comparative effect Effects 0.000 description 62
- 210000003491 skin Anatomy 0.000 description 61
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 52
- 235000014655 lactic acid Nutrition 0.000 description 26
- 239000004310 lactic acid Substances 0.000 description 26
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 24
- 239000000463 material Substances 0.000 description 20
- 238000003756 stirring Methods 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 15
- 229960001340 histamine Drugs 0.000 description 12
- 238000005303 weighing Methods 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 206010015150 Erythema Diseases 0.000 description 10
- 239000012141 concentrate Substances 0.000 description 10
- 230000001976 improved effect Effects 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 239000013566 allergen Substances 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 210000003630 histaminocyte Anatomy 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 230000001815 facial effect Effects 0.000 description 7
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 7
- 229960001660 histamine phosphate Drugs 0.000 description 7
- 230000008439 repair process Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000008313 sensitization Effects 0.000 description 6
- 206010002198 Anaphylactic reaction Diseases 0.000 description 5
- 241000700198 Cavia Species 0.000 description 5
- 229920002307 Dextran Polymers 0.000 description 5
- 208000003455 anaphylaxis Diseases 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 229940064064 purslane extract Drugs 0.000 description 5
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 210000003651 basophil Anatomy 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 238000006748 scratching Methods 0.000 description 4
- 230000002393 scratching effect Effects 0.000 description 4
- 230000008591 skin barrier function Effects 0.000 description 4
- 210000004927 skin cell Anatomy 0.000 description 4
- 210000000434 stratum corneum Anatomy 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 229960003657 dexamethasone acetate Drugs 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 150000003278 haem Chemical class 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 2
- 229940015975 1,2-hexanediol Drugs 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102100024304 Protachykinin-1 Human genes 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 101800003906 Substance P Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 238000010523 cascade reaction Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 230000037067 skin hydration Effects 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009044 synergistic interaction Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- 102000004363 Aquaporin 3 Human genes 0.000 description 1
- 108090000991 Aquaporin 3 Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010016322 Feeling abnormal Diseases 0.000 description 1
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102100039065 Interleukin-1 beta Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 244000137852 Petrea volubilis Species 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 206010054786 Skin burning sensation Diseases 0.000 description 1
- 206010040830 Skin discomfort Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000003566 TRPV1 Human genes 0.000 description 1
- 101150016206 Trpv1 gene Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000006757 chemical reactions by type Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003229 cytophilic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to a composition with effects of relaxing, anti-allergic and antipruritic and application thereof, and belongs to the technical field of cosmetics. The composition with the effects of relaxing and relieving allergy and itching comprises the following components in parts by weight: 0.1 to 1 part of kava root extract, 0.01 to 0.5 part of olive leaf extract and 0.01 to 5 parts of black truffle extract. According to the invention, the kava root extract, the olive leaf extract and the black truffle extract are compounded according to a specific proportion, the three components are synergistic, the burning sensation and the stinging sensation of skin can be relieved immediately through the multi-channel comfort and anti-sensitization effect, the damaged skin can be repaired efficiently, the sources of raw materials are natural, and the composition is suitable for various crowds, especially sensitive crowds. In addition, the composition of the invention can improve the moisturizing performance of the composition and the cold resistance and stability of the composition by introducing the glycerol glucoside or the polyol humectant with a polyhydroxy structure.
Description
Technical Field
The invention belongs to the technical field of cosmetics, and particularly relates to a composition with effects of relaxing, relieving, resisting sensitization and relieving itching and application thereof.
Background
In recent years, allergic people have been rapidly increasing with changes in dietary structure, environmental pollution, and pressure of work and life. Skin sensitivity has become a global potential and is a skin problem of daily concern to consumers.
Sensitive skin is a highly intolerant skin condition that is susceptible to irritation by various external factors and produces subjective symptoms such as stinging, burning, tightening, itching, etc. The formation cause is very complex, and is the result of the combined action of multiple factors, and can be divided into exogenous factors and endogenous factors. Among the exogenous factors are: skin allergy or injury is caused or aggravated by physical factors (ultraviolet rays, heat, cold, mechanical injury, etc.), chemical factors (excessive degreasing of surfactants, chemical solvents, sun-screening agents, etc.), biological factors (bacteria, mold, germs, etc.), lifestyle (spicy stimulation of diet, alcohol, etc.), psychological factors (increase of stress, agitation of emotion, etc.); endogenous factors are: race, age, sex, genetics, endocrine factors, disease, etc.
The mechanism by which type I allergic reactions occur can be broadly divided into three phases: (1) sensitization phase: after entering the body, the allergen can selectively induce allergen-specific B cells to generate antibody responses, and the antibodies are combined with the surfaces of mast cells and basophils to enable the body to be in a sensitization state for the allergen, wherein the sensitization state can be maintained for a plurality of months or longer generally, and can automatically and gradually disappear if the allergen is not contacted for a long time; (2) excitation stage: when the same allergen reenters the body, the cells release bioactive mediums (histamine, prostaglandin, leukotriene, platelet activating factor and the like) by specific binding with antibodies on the surfaces of sensitized mast cells and basophils, thereby causing smooth muscle contraction, capillary vessel expansion and permeability enhancement and gland secretion increase; (3) effect phase: refers to the stage in which bioactive mediators act on effector tissues and organs to cause local or systemic allergic reactions. The reaction can be classified into early phase reaction and late phase reaction according to the rate and duration of the reaction. Early phase reactions are mainly caused by histamine, usually occurring within seconds of allergen exposure, and can last for several hours, and late phase reactions are caused by prostaglandins, leukotrienes, platelet activating factors, etc., and reactions occur 6-12 hours after allergen stimulation, and can last for several days.
In general, skin allergies are accompanied by the occurrence of skin inflammatory reactions. The skin inflammatory reaction occurs by the mechanism that skin is affected by external factors (such as machinery, physics, chemistry and the like) to damage skin barriers, so that water-soluble components NMF, lipid and protein of intercellular lipid bilayer are lost, a large amount of primary inflammatory factors (such as tumor necrosis factor TNF-alpha, interleukin IL 1-alpha and the like) are released, the cytophilic inflammatory factors are combined with mast cells and keratinocytes in a body to generate cascade reaction, pro-inflammatory mediators IL-6 and IL-8 and secondary inflammatory factors (such as cyclooxygenase COX-2, prostaglandin PGE2 and the like) are further released, the cascade reaction is aggravated, blood vessels are dilated, and simultaneously, itching mediators and overactive thermal receptors are released, so that sensory nerves are more sensitive, and itching, burning, stinging and even erythema and rash are generated to different degrees.
At present, most of the commercially available cosmetics for relieving and resisting allergy are used for blocking the occurrence of anaphylactic reaction through the single way of inhibiting early phase reaction, have little effect on anaphylactic reaction caused by other signal ways and cannot immediately calm and relieve skin discomfort. Therefore, it is important to develop a safe and efficient composition which can inhibit allergic reaction through multiple ways, is suitable for sensitive muscles and can calm, relieve and repair damaged skin immediately.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide a composition which is safe, efficient, can inhibit allergic reaction through multiple ways, is applicable to sensitive muscles and can calm and relieve and repair damaged skin in real time.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
in a first aspect, the invention provides a composition with the effects of relaxing and anti-allergic and antipruritic, which comprises the following components in parts by weight: 0.1 to 1 part of kava root extract, 0.01 to 0.5 part of olive leaf extract and 0.01 to 5 parts of black truffle extract.
The inventor researches and discovers that the kava root extract, the olive leaf extract and the black truffle extract are compounded according to a specific proportion, the three components are synergistic, and the TRPV1 pathway is inhibited to block the neuron to transmit information, so that the excessive reaction of sensory nerves is avoided, and when skin neuron cells are stimulated, discomfort such as stinging, burning, itching, swelling and the like generated by the skin under external stimulation is relieved instantaneously, and the tolerance of the skin to external stimulation is effectively improved; the composition provided by the invention also can be used for avoiding oxidative damage of mast cells and basophils by removing free radicals, so that the cells are always in a stable state, even under the stimulation of stronger allergens, immune allergy is not easy to occur, the mast cells and the basophils are not degranulated, allergic media are not easy to release, meanwhile, the release of histamine is inhibited, the allergic media are reduced from a terminal, the inflammatory reaction of skin is lightened, and skin itching and red swelling discomfort are further relieved. In addition, the composition can also directly reach the bottom layer of human skin cells, activate the self-repairing function of skin basal cells, further effectively repair damaged skin cells, improve the skin barrier function and improve the immunity of the skin cells, thereby improving the skin sensitive state.
In addition, the composition has natural raw material sources, can immediately relieve burning sensation and stinging sensation of skin through multi-channel comfort and anti-sensitization, can efficiently repair damaged skin, and is suitable for various people, especially sensitive people.
As a preferred embodiment of the composition of the present invention, kava root extract is 0.15-0.8 parts, olive leaf extract is 0.12-0.3 parts, black truffle extract is 0.05-3 parts.
The inventor researches find that the kava root extract, the olive leaf extract and the black truffle extract can enable the composition to have more efficient and rapid relieving of skin itch and red swelling uncomfortable feeling within the proportion range, and are beneficial to improving the repair performance of the composition on damaged cells. In addition, the composition contains more black truffle extract, which is more beneficial to promoting HAS-2 expression to synthesize hyaluronic acid, so that the moisturizing performance of the composition is improved, and the generation of inflammatory factor NO can be enhanced and hindered, so that the composition HAS more excellent anti-inflammatory performance.
As a preferred embodiment of the composition of the present invention, the composition further comprises a humectant selected from at least one of glucosyl, glycerol, butylene glycol, dipropylene glycol.
The inventor researches and discovers that after the glycerol glucoside or the polyol humectant with a polyhydroxy structure is introduced and compounded with the kava root extract, the olive leaf extract and the black truffle extract, the composition and water molecules are facilitated to form hydrogen bonds, so that the moisture retention performance of the composition can be improved, the formation of a lattice structure by directional ordering of the water molecules under the low-temperature condition can be avoided, the solidifying point of a system is effectively reduced, the cold resistance of the composition is improved, and the composition has better stability.
As a more preferred embodiment of the composition of the present invention, the humectant is glucosyl.
The inventor of the invention conducts a great deal of experimental research on components of the humectant, and discovers that the glyceroglycosides can directly reach the dermis layer, endogenous promote the synthesis of AQP3 aquaporin, realize deep long-acting water supplementing and water locking performances, and after being compounded with kava root extract, olive leaf extract and black truffle extract, the components are more beneficial to synergistic interaction, the release amount of inflammatory factors IL-1 alpha and IL-1 beta is obviously reduced, and further inhibit the degranulation reaction of mast cells, thereby improving skin inflammation, relieving skin redness, allergy and the like, and the composition has better anti-allergic and antipruritic performances. And other types of moisturizers are adopted, so that the moisturizing agent can only act on the surface of the skin, can not realize long-acting moisturizing performance, can generate certain irritation to the skin and mucous membrane, is easy to cause anaphylactic reaction, and is unfavorable for the use of sensitive people.
As a preferred embodiment of the composition of the present invention, the humectant is 0.01 to 2 parts by weight.
The inventor researches find that the humectant is compounded with kava root extract, olive leaf extract and black truffle extract according to a certain proportion in the above range, so that the synergistic interaction among the components is facilitated, the composition has more excellent skin soothing and damaged skin repairing performances, and the cosmetic containing the composition can have more excellent stability and moisturizing performances. The humectant is added in a small amount, so that the long-acting moisturizing performance and the stability of the composition in the product can not be achieved; the humectant is added in a large amount, so that skin is excessively strong in transdermal absorbability, stimulus is easier to enter the skin, nervonic anaphylaxis is enhanced, in addition, the limitation of the composition in formula application is increased, the sticky feeling of a product is additionally increased, and the experience is poor.
As a more preferable embodiment of the composition of the present invention, the humectant is 0.01 to 0.5 parts by weight.
The inventor of the present invention has found that the humectant of the present invention can provide a composition having a longer moisturizing performance, better stability and optimal skin feel experience in cosmetics, by using the parts by weight of the humectant in the above range.
As a most preferred embodiment of the composition according to the invention, the composition comprises the following components in parts by weight: 0.2 to 0.7 part of kava root extract, 0.15 to 0.2 part of olive leaf extract, 0.1 to 1 part of black truffle extract and 0.03 to 0.5 part of humectant.
The inventor researches find that the kava root extract, the olive leaf extract, the black truffle extract and the humectant are compounded according to the proportion, so that the synergistic effect among the components is optimal, the composition has optimal anaphylactic reaction inhibition effect, and the effects of calming, relieving and repairing damaged skin are optimal.
In a second aspect, the invention also provides application of the composition with effects of relaxing and relieving allergy and itching in preparation of cosmetics.
In a third aspect, the present invention also provides a cosmetic comprising the above composition having soothing and antiallergic antipruritic effects.
As a preferred embodiment of the cosmetic according to the present invention, the cosmetic is in a form selected from the group consisting of cream and/or aqueous solutions; the cream comprises a soothing essence cream, and the water agent comprises a soothing essence spray and/or a soothing essence.
The inventor researches find that the composition with the effects of relaxing, relieving, resisting sensitization and relieving itching can be applied to cosmetics in various dosage forms, and the relaxing, repairing, resisting sensitization and relieving itching effects of the cosmetics are effectively improved under the condition that the stability of an original cosmetic system is not affected.
As a more preferred embodiment of the cosmetic of the present invention, the composition having the efficacy of soothing and anti-allergic and antipruritic is 0.12 to 8.5% by mass based on the total mass of the cosmetic.
The addition amount of the composition with the effects of relaxing, relieving, resisting and relieving itching in the cosmetic is within the range, so that the cosmetic has longer-acting moisturizing performance and more excellent stability, achieves the effects of immediately relaxing, relieving and repairing damaged skin, has excellent relaxing, resisting, relieving itching and greatly improving the skin feel of the cosmetic.
Compared with the prior art, the invention has the beneficial effects that:
(1) The kava root extract, the olive leaf extract and the black truffle extract are compounded according to a specific proportion, the three components are synergistic, the burning sensation and the stinging sensation of skin can be relieved immediately through the multi-channel comfort and anti-sensitization effect, the damaged skin can be repaired efficiently, the sources of raw materials are natural, and the composition is suitable for various crowds, especially sensitive crowds;
(2) According to the invention, after the glycerol glucoside or the polyol humectant with a polyhydroxy structure is introduced and compounded with the kava root extract, the olive leaf extract and the black truffle extract, the composition and water molecules are facilitated to form hydrogen bonds, so that the moisture retention performance of the composition can be improved, the formation of a lattice structure by directional ordering of the water molecules under a low-temperature condition can be avoided, the freezing point of a system is effectively reduced, the cold resistance of the composition is improved, and the composition has better stability.
Detailed Description
The technical scheme of the invention is further described below by referring to examples. It will be apparent that the described embodiments are only some, but not all, embodiments of the invention. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention. The methods or operations used in the examples, unless specifically indicated, are conventional methods or conventional operations in the art.
In the following examples and comparative examples of the present invention: kava root extract was purchased from western amp green biotechnology limited; the olive leaf extract was purchased from scow biotechnology limited; black truffle extract is purchased from modern bronsted biotechnology (Jiangsu) limited; glycerol glucoside was purchased from Qingdao Cork blue Biotechnology development Co.
Examples 1 to 17 and comparative examples 1 to 16
Examples 1 to 17 and comparative examples 1 to 16 are soothing essence sprays of the present invention comprising a composition having soothing and antiallergic antipruritic effects. The components and parts by weight of the soothing concentrate sprays of examples 1 to 17 and comparative examples 1 to 14 are shown in Table 1 below, with the total parts by weight being: 100 parts.
Examples 1 to 17 and comparative examples 1 to 14 were sprayed with a soothing essence: the preservative consists of p-hydroxyacetophenone, 1, 2-pentanediol and 1, 2-hexanediol (the mass ratio of the components in the preservative is p-hydroxyacetophenone to 1, 2-pentanediol to 1, 2-hexanediol=1:1.5:3. The moisturizing agents of the soothing essence sprays of examples 8-14 and comparative examples 1-13 are all glyceroglycosides, the moisturizing agent of the soothing essence spray of example 15 is butanediol, the moisturizing agent of the soothing essence spray of example 16 is dipropylene glycol, and the moisturizing agent of the soothing essence spray of example 17 is propylene glycol.
TABLE 1
Comparative examples 15 to 16 were also provided. The soothing concentrate spray of comparative example 15 differs from example 8 only in that: replacing the kava root extract with the purslane extract with the same weight part; the soothing concentrate spray of comparative example 16 differs from example 8 only in that: replacing all the olive leaf extract with the purslane extract with the same weight part; the other components and parts by weight of the soothing concentrate sprays of comparative examples 15 to 16 were the same as in example 8.
The preparation method of the soothing essence spray of examples 1 to 17 and comparative examples 1 to 16 comprises the following steps:
s1, weighing the component C according to a proportion, heating to 80 ℃, and stirring until the component C is completely dissolved to obtain a phase C;
s2, weighing the component A according to a proportion, heating to 80 ℃, and stirring and dispersing uniformly to obtain a phase A;
s3, cooling the phase A in the step S2 to 45 ℃, adding the component B, and uniformly mixing to obtain a mixed material;
and S4, cooling the mixed material in the step S3 to 37 ℃, adding the phase C in the step S1, stirring and dispersing uniformly, and filtering through a 500-mesh filter cloth to obtain the soothing essence spray.
Effect example 1
To verify the soothing properties of the compositions of the present invention having soothing, anti-allergic and antipruritic effects, the soothing essence sprays of examples 1 to 17 and comparative examples 1 to 16 were subjected to lactic acid stinging tests.
Lactic acid stinging positive evaluation method: under the environment of constant temperature (21 ℃ +/-2 ℃) and constant humidity (50% +/-10%), 50 mu L of lactic acid aqueous solution (the mass percent of lactic acid in the lactic acid solution is 10%) is smeared on the nasolabial sulcus and any side cheek, subjective symptoms of a subject are inquired at 2.5min and 5min respectively, the subjects are scored according to a 4-score method (the score is 0 score, 1 score, 2 score and 3 score, wherein 0 score indicates no stinging sensation, 1 score indicates light stinging sensation, 2 score indicates moderate stinging sensation and 3 score indicates heavy stinging sensation), the sum of the scores of the two scores (2.5 min+5 min) is the stinging score of the lactic acid, and the subjects with the stinging score of more than or equal to 3 score are the stinging reaction of the lactic acid.
Test object: people with positive lactic acid stinging (i.e. people with a lactic acid stinging score of 3) who are sensitive to muscle have no serious systemic diseases, no immunodeficiency or autoimmune diseases, have not received facial skin treatment, cosmetic or other actions that may affect the outcome.
Number of test persons: 20 people/group.
The testing method comprises the following steps:
(1) The tested part cannot use any cosmetics or medicines on the test day, the skin surface moisture is sucked by using dry facial tissues after the tested part is cleaned by using clear water, the tested object can not drink water and eat any food in the period of sitting still for 30 minutes in a constant-temperature and constant-humidity environment, and the tested object is kept relaxed to avoid touching the face; symmetrically placing two filter paper sheets at the nasolabial sulcus of the test object;
(2) 50 mu L of lactic acid aqueous solution (the mass percent of lactic acid in the lactic acid solution is 10%) is sucked by a pipette and randomly dropped on one side of a filter paper sheet, and 50 mu L of distilled water is dropped on the opposite side; subjective symptoms of the subjects were asked at 2.5min and 5min, respectively, scored by a 4-score method (score 0, 1,2, 3, wherein 0 indicates no tingling, 1 indicates light tingling, 2 indicates moderate tingling, 3 indicates heavy tingling), the sum of the scores of the two scores (2.5min+5 min) was the lactic acid tingling score, and the data recorded as D using the lactic acid tingling score prior to the test sample 0 . If the interviewee is intolerant in the test process, the two side test objects can be removed, and the scores of the remaining time points are consistent with the scores when the test objects are removed.
(3) Immediate relief efficacy evaluation: distributing test samples, after cleaning the face of a test object, uniformly smearing 3-5 pump materials (the total amount is about 0.5 mL) on the nasal and labial sulcus, massaging until the test object is completely absorbed, and grading the test object after 30min, and performing questionnaire and query evaluation on the instant relieving effect of the test object (the evaluation items of the instant relieving effect are instant relieving skin burning sensation, instant relieving stinging and itching and instant reducing myo-redness, the grading of each test sample is the average value of the grading of all test objects of the test sample on the same evaluation item), wherein the grading standard is shown in the following table 2, and the higher the grading is, the better the test object considers the instant relieving performance of the test sample;
(4) Long-acting relaxation performance test: after the test sample is distributed, 3-5 pump materials (the total amount is about 0.5 mL) are uniformly smeared on the face of a test subject after the face is cleaned, the test subject is massaged until the test subject is completely absorbed, and the test sample is used once in the morning and evening, and is used twice a day, and other skin care products or products with similar effects are not used in the period; and (3) carrying out return visit 2 weeks and 4 weeks after the continuous use of the product, repeating the steps (1) - (2), carrying out lactic acid stinging test, and respectively recording the lactic acid stinging score of each test object 2 weeks and 4 weeks after the continuous use of the product.
(5) Calculating the average value of the lactic acid stinging scores obtained by the test subjects of the test sample in the same time in the lactic acid stinging test, wherein the average value is the lactic acid stinging score of the test sample and is recorded as D respectively 14 And D 28 (wherein D 14 D for the lactic acid stinging score after 2 weeks of use 28 For lactic acid stinging score after 4 weeks of use).
The rate of change of the lactic acid stinging score was calculated as follows:
wherein D is n For a lactic acid stinging score after n days of continuous use of the product, n=14 or 28.
TABLE 2
| Scoring criteria | Scoring/scoring |
| Very agree to | 7 |
| Comparison and acceptance | 6 |
| Some is agreed with | 5 |
| Neither is considered nor is it objectionable | 4 |
| Some differences are in | 3 |
| Comparison of disagreement | 2 |
| Very different to be identified | 1 |
The test results are shown in table 3 below.
TABLE 3 Table 3
/>
From table 3, it can be seen that the soothing essence spray prepared in examples 1 to 17 of the present invention has a good immediate soothing performance, and has an obvious effect of improving the stinging feeling of lactic acid after continuous use for 2 weeks and 4 weeks, so that the discomfort of skin caused by external stimulation can be effectively relieved when skin neuron cells are stimulated, the tolerance of skin to external stimulation can be effectively improved after long-term use, the skin barrier function can be improved, and the skin cell immunity can be improved, which indicates that the soothing essence spray of the present invention has a good soothing performance. Among them, the instant soothing performance and the long-acting soothing performance of the soothing essence spray of example 10 were optimal.
As is clear from the comparison between the examples 8 and the comparative examples 1 to 6, too much or too little amount of the active ingredient in the soothing essence spray may cause imbalance in the proportions of the components, and a good synergistic effect may not be achieved, so that the soothing performance of the soothing essence spray may be lowered.
As is clear from the comparison of example 8 with comparative examples 7 to 13, the soothing essence sprays of comparative examples 7 to 13 were significantly reduced in the performance of improving skin barrier in the absence of one or more active ingredients, and could not achieve the effect of relieving discomfort caused by external stimulus to the skin, and were inferior in soothing performance. While comparative example 8 and comparative example 14 show that the soothing essence spray of comparative example 14 has little soothing performance without the composition of the present invention having soothing and anti-allergic and antipruritic effects.
As is clear from the comparison between the example 8 and the comparative examples 15 to 16, the replacement of kava root extract or olive leaf extract with purslane extract having soothing and repairing effects, the soothing essence spray of the comparative examples 14 to 15 is poor in improving the lactic acid stinging, and only the superposition of soothing properties among the components cannot achieve a good synergistic effect.
Effect example 2
To further verify the soothing properties of the compositions of the present invention having soothing, anti-allergic and antipruritic effects, the soothing essence sprays of examples 1 to 17 and comparative examples 1 to 16 were subjected to skin erythema index property test.
The test principle is as follows: the skin Erythema Index (EI) reflects the condition of facial capillaries, visually reflects the verification degree, and is an objective evaluation method; the lower the skin erythema index, the better the product is to repair the skin and improve the skin erythema response.
Test object: people with positive lactic acid stinging (i.e. score > 3) sensitive muscles have no serious systemic disease, no immunodeficiency or autoimmune disease, no facial skin treatment, no beauty and no other actions that might affect the result.
Number of test persons: 20 people/group.
The testing method comprises the following steps:
(1) The test subjects uniformly clean the face, suck the face with chipless absorbent dry paper towel, sit still for 30min under the environment of constant temperature and constant humidity, shoot the face image with a VISIA skin image analyzer, observe the red differential value of the face, record as an initial value X 0 ；
(2) After the test sample is distributed, 3-5 pump materials (the total amount is about 0.5 mL) are uniformly smeared on the face of a test subject after the face is cleaned, the test subject is massaged until the test subject is completely absorbed, and the test sample is used once in the morning and evening, and is used twice a day, and other skin care products or products with similar effects are not used in the period; after the product is continuously used, the return visit is respectively carried out on the 7 th day, the 14 th day, the 21 st day and the 28 th day, the image acquisition is carried out again, the red facial differentiation value is observed, and the red facial differentiation value is recorded as a measured value X n (n is the number of days of continuous use of samples);
(3) An average value of the facial red differentiation values of the test subjects of the test sample at the same time, which is the heme EI value of the test sample, is calculated.
The calculation formula of the rate of change of the heme EI value is as follows:
wherein X is n For heme EI values after n days of continuous use of the product, n is 7, 14, 21, 28.
The test results are shown in table 4 below.
TABLE 4 Table 4
/>
/>
/>
From table 4, it can be seen that the soothing essence spray prepared in examples 1 to 17 of the present invention can rapidly and efficiently reduce the skin erythema index, is beneficial to repairing damaged skin, improving skin erythema reaction, effectively reducing skin inflammatory reaction, and further relieving and improving skin sensitivity state. Among them, the soothing essence spray of example 10 was the best in soothing performance.
As is clear from the comparison between the examples 8 and the comparative examples 1 to 6, too much or too little amount of the active ingredient in the soothing essence spray may cause imbalance in the proportions of the components, and a good synergistic effect may not be achieved, so that the soothing performance of the soothing essence spray may be lowered.
Comparative example 8 and comparative examples 7 to 13 show that the soothing essence sprays of comparative examples 7 to 13 are inferior in soothing repair performance to skin in the absence of one or more active ingredients, and are not effective in repairing damaged cells and reducing inflammatory reaction of skin. In contrast, comparative example 8 and comparative example 14 show that the soothing essence spray of comparative example 14 has little anti-inflammatory and soothing properties without the composition of the present invention having the soothing and anti-allergic and antipruritic effects.
As is clear from the comparison between the examples 8 and the comparative examples 15 to 16, the replacement of the kava root extract or the olive leaf extract with the purslane extract having the soothing and repairing effects, the soothing essence spray of the comparative examples 14 to 15 has the property of reducing the skin erythema index to be reduced, and the effect of good synergy cannot be achieved only by the superposition of the soothing properties of the components.
Effect example 3
To further verify the anti-allergic antipruritic properties of the composition of the present invention having the effects of soothing and anti-allergic antipruritic, the anti-allergic antipruritic properties were tested by spraying the soothing essences of examples 1 to 17 and comparative examples 1 to 16.
The test principle is as follows: dextran can cause mast cells to release histamine to induce inflammatory reaction, so that mice can produce skin itch, while histamine can promote various cells and tissues to synthesize and secrete proinflammatory cytokines and chemokines such as IL-1A, IL-1B, IL-6, IL-8 or RANTES, and the like, so as to promote allergy-inflammatory reaction to cause itch; histamine also stimulates nerve endings in the skin, directly causing itching and releasing Substance P (SP), promoting degranulation of mast cells to release histamine further causing itching; meanwhile, scratching caused by itch can lead to release of inflammatory mediators, and increase severity of itch. According to the invention, by establishing a dextran-induced mouse pruritus model, the anti-allergic itching relieving effect of a sample to be tested is observed.
Reagent: the sample to be tested, the compound dexamethasone acetate emulsifiable paste, deionized water, normal saline, histamine phosphate and dextran.
The test components are as follows: model group (only containing deionized water), control group (only containing compound dexamethasone acetate cream) and sample group (each sample to be tested is one sample group, and total 33 sample groups); the administration method for the histamine tolerance test and the scratching frequency test comprises the following steps: the model group was 0.5 mL/piece, the control group was 0.5 g/piece, and the sample group was 0.5 mL/piece.
Histamine tolerance test:
(1) Test object: the weight of 10 guinea pigs per group is 250-300 g, and each group comprises 5 female mice and 5 male mice.
(2) The testing method comprises the following steps: shearing the right hind dorsum of guinea pig 48 hr before experiment, and depilating with depilating agent to obtain depilating product with area of about 1cm 2 The method comprises the steps of carrying out a first treatment on the surface of the On the day of the experiment, the skin of the dehaired part is gently scratched by fine sand paper to make the dehaired part red until bleeding is not caused, and the dehaired part is given to the wound partAnd then, applying a histamine phosphate solution with the mass percent of 0.05%, wherein the consumption of the histamine phosphate solution is 30 mu L/mouse, if the guinea pigs do not have itching reaction (namely, licking the action of the right hind foot wound part), then, applying the histamine phosphate solution for 1 time, repeating the operation until the itching reaction is stopped, recording the times and the total consumption of the applied histamine phosphate solution, accumulating the total amount of the histamine phosphate given by each guinea pig, and obtaining the average value of the total amount of the histamine phosphate of 10 guinea pigs in each test group, namely, obtaining the histamine tolerance of the test group.
And (3) scratching times test:
(1) Test object: SPF-class Kunming mice, 10 mice/group, guinea pigs weight of 18-21 g, 5 female mice and 5 male mice in each group;
(2) The testing method comprises the following steps: the mice are administrated by intravenous injection at the tail, and then the dextran injection with the mass percent of 0.025 percent is administrated by injecting 0.05mL/10g of mice, the front paws of the mice scratch the head, the rear paws scratch the trunk and the mouth bite all parts of the whole body are taken as pruritus indicators, the pruritus times of the mice within 30min are observed and recorded, and the average value of the pruritus times of 10 mice in each test group is calculated to be the scratching times of 30min of the test group.
The test results are shown in table 5 below.
TABLE 5
From Table 5, it can be seen that the soothing essence sprays of examples 1 to 17 of the present invention can effectively improve the histamine tolerance of guinea pigs, and at the same time, can also relieve the skin itch reaction caused by dextran, and has good anti-allergic and antipruritic effects.
As is clear from the comparison of example 8 with comparative examples 1 to 6, the soothing essence sprays of comparative examples 1 to 6 were deteriorated in the anti-allergic and antipruritic properties due to the unbalance of the ratio of the active ingredients among the components caused by the large or small amount of a certain component.
Comparative example 8 and comparative examples 7 to 13 it is understood that the soothing essence sprays of comparative examples 7 to 13 are reduced in histamine tolerance and reduced in anti-allergic antipruritic effect due to the lack of one or two active ingredients. And without the composition with the effects of relaxing and anti-allergic and antipruritic, the anti-allergic and antipruritic effects of the relaxing essence spray of the comparative example 14 are equivalent to those of deionized water.
As can be seen from comparative examples 8 and 15 to 16, the anti-allergic and antipruritic effects of the soothing essence sprays of comparative examples 14 to 15 were similar to the performance of the compound dexamethasone acetate cream by replacing kava root extract or olive leaf extract with purslane extract having soothing and repairing effects.
Effect example 4
In order to verify the moisturizing performance of the composition with the effects of soothing and relieving allergy and itching of the present invention, the moisturizing efficacy test was performed by spraying the soothing essence of example 8, examples 15 to 17 and comparative examples 7 to 14.
Experimental principle: the moisture content of the skin is reflected by testing the skin capacitance value based on the maximum dielectric constant of water. Transdermal water loss (Transepodermal water loss, TWEL) measures the change in vapor pressure of moisture adjacent to the skin surface. TEWL value indicates the loss of water from the stratum corneum, and is an important criterion for evaluating barrier function of the stratum corneum. The lower the TWEL value of the skin, the better the barrier function of the skin, and conversely the worse. The hydration and transdermal water loss values of the skin stratum corneum before and after the application of the samples were tested by Corneometer CM 825 and Tewameter TM 300, and the moisturizing properties of the samples were reflected by these indices.
Test instrument: corneometer CM 825 (CK electronic GmbH, germany); tewameter TM 300 (CK electronic GmbH, germany).
Test object: volunteers with healthy skin, no history of skin disease and allergy were selected for each test sample. Because of no personal difference among limbs, the device is suitable for being used as a detected part, and the proper area of the antecarpal flexion side area of a volunteer is selected as a test area.
Number of test persons: 20 people/group.
Test conditions: volunteers were allowed to stand still in an environment with a Relative Humidity (RH) of 50% + -2% or less at room temperature of 25+ -2 ℃ or less, and the examined parts were exposed 10min before measurement, and the hydration degree of the horny layer and the transdermal water loss (recorded as control values) were measured, respectively.
The testing method comprises the following steps: when the moisturizing effect of the sample is determined, a coating test ending in a short time is suitably performed. The test sample of 0.5mL was applied to the test site, massaged until the absorption was complete, and the moisture content of the stratum corneum and the percutaneous loss of the epidermis before and after use (recorded as test values) were measured 30min and 2h after use of the test sample, respectively.
The skin hydration rate and TEWL rate were calculated as follows:
the test results are shown in table 6 below.
TABLE 6
As can be seen from table 6, the soothing essence sprays of examples 8 and 15 to 17 of the present invention have higher skin hydration rate and reduced rate of change of TWEL, indicating that the composition with soothing and antiallergic and antipruritic effects of the present invention is favorable for the soothing essence spray to form hydrogen bond with water molecules, so that it has excellent moisturizing property.
Comparative example 8 and comparative examples 7 to 9 show that the absence of a certain active ingredient results in a decrease in the moisturizing performance of the soothing concentrate spray of comparative examples 7 to 9. Whereas the soothing essence sprays containing no humectant and only a single active ingredient, the soothing essence sprays of comparative examples 10 to 12 were inferior in moisturizing performance; the soothing essence spray of comparative example 13 only contains a humectant, has certain moisturizing performance, but has poor moisturizing effect; whereas the soothing concentrate spray of comparative example 14 had little moisturizing performance without the composition of the present invention having soothing and anti-allergic and antipruritic effects.
Effect example 5
To verify the safety of the products of the soothing essence spray of the present invention, the soothing essence sprays of example 8, examples 15 to 17, and comparative examples 7 to 14 were subjected to a human skin patch test.
The testing method comprises the following steps: the test groups were each 20 females and 10 males, each of which was treated with the soothing essence sprays of examples 8, 15 to 17 and comparative examples 7 to 14, and 0.02mL of the test sample was placed in a plaque tester, and applied to the forearm of the subject by a hypoallergenic tape, and after 24 hours, the test sample was removed, and skin reactions were observed at 0.5 hours, 24 hours and 48 hours after the removal, and the results were recorded according to the skin reaction classification standard in cosmetic safety Specification (2015). The identification criteria for the skin irritation test are shown in table 7.
TABLE 7
The test results are shown in table 8 below.
TABLE 8
/>
As can be seen from Table 8, the soothing concentrate sprays of examples 8 and 15-17 of the present invention have good safety performance and do not cause irritation to the skin.
Examples 18 to 21 and comparative example 17
Examples 18 to 21 and comparative example 17 are soothing creams of the present invention. The soothing essence cream contains the composition with the effects of soothing and relieving allergy and itching.
The components and mass percentages of the soothing essence cream of examples 18 to 21 and comparative example 17 are shown in the following table 9, and the unit of mass percentages of the components is: percent of the total weight of the composition. The total mass of the soothing cream of example 18 and comparative example 17 was 100%.
TABLE 9
/>
Examples 19 to 21 are also provided. The soothing essence cream of example 19 differs from example 18 only in that: all the glucosyl glycosides are replaced by butanediol with the same mass percentage; the other components and mass percentages of the soothing essence cream of example 19 are the same as those of example 18. The soothing essence cream of example 20 differs from example 18 only in that: all the glucosyl glycosides are replaced by dipropylene glycol with the same mass percentage; the other components and mass percentages of the soothing essence cream of example 20 are the same as those of example 18. The soothing essence cream of example 21 differs from example 18 only in that: all the glucosyl glycosides are replaced by propylene glycol with the same mass percentage; the other components and mass percentages of the soothing essence cream of example 21 are the same as those of example 18.
The preparation method of the soothing essence cream of examples 18 to 21 and comparative example 17 comprises the following steps:
s1, weighing the component B2 according to a proportion, and stirring and dispersing uniformly to obtain a phase B2;
s2, weighing the component D according to a proportion, and stirring and dissolving completely to obtain a phase D;
s3, weighing the component E according to a proportion, heating to 70 ℃ at constant temperature, and stirring and dissolving completely to obtain the phase E;
s4, weighing the component F according to a proportion, heating to 80 ℃, and stirring and dissolving completely to obtain a phase F;
s5, weighing the component A according to a proportion, and heating to 80 ℃ at constant temperature to obtain a phase A;
s6, weighing the component B according to a proportion, uniformly dispersing the component B1 under a uniform condition, adding the phase B2 in the step S1, uniformly dispersing, heating to 80 ℃ at constant temperature, and preserving heat for 20min to obtain a mixed material A;
s7, adding the mixed material A in the step S6 into the phase A in the step S5 under the homogenizing condition, homogenizing for 2min, adding the component C, homogenizing for 3min, and stirring until the mixed materials are uniformly mixed to obtain a mixed material B;
s8, cooling the mixed material B in the step S7 to 70 ℃, adding the D phase in the step S2 and the E phase in the step S4, and stirring and dispersing uniformly to obtain a mixed material C;
s9, cooling the mixed material C in the step S8 to 45 ℃, adding the component G and the phase F in the step S4, and stirring and dispersing uniformly to obtain a mixed material D;
and S10, cooling the mixed material D in the step S9 to 38 ℃, and filtering through 200-mesh filter cloth to obtain the soothing essence cream.
Effect example 6
To further verify the stability of the soothing essence cream of the present invention, the soothing essence creams of examples 18 to 21 and comparative example 17 were subjected to a stability test.
The testing method comprises the following steps: the test samples (4 groups of the same amount are measured for each test sample) are packaged by transparent packaging materials, and are respectively and statically placed under the conditions of normal temperature (25 ℃), illumination, 40 ℃ and minus 18 ℃ for 30 days of continuous observation, taken out on the 7 th day, 15 th day and 30 th day respectively, and are restored to room temperature (25 ℃) to observe the change condition of the sample state.
The test results are shown in tables 10 to 13 below.
Table 10 test conditions: normal temperature (25 ℃ C.)
Table 11 test conditions: illumination of
Table 12 test conditions: 40 DEG C
Table 13 test conditions: -18 DEG C
From tables 10 to 13, it can be seen that the soothing essence cream of examples 18 to 21 of the present invention has good stability under the conditions of normal temperature, illumination and 40 ℃; while the soothing essence cream prepared by using the glyceroglycosides as the humectant still has good cold-resistant stability for 30 days under the low-temperature (-18 ℃) condition, the soothing essence creams of examples 19-21 prepared by using other types of humectants begin to have the phenomenon of surface coarsening under the low-temperature (-18 ℃) condition, and have poor cold-resistant stability.
Examples 22 to 25 and comparative example 18
Examples 22 to 25 and comparative example 18 are soothing essences of the present invention. The soothing essence comprises the composition with the effects of soothing and relieving allergy and itching.
The components of the soothing essence of example 22 and comparative example 18 and their mass percentages are shown in table 14 below, the units of the mass percentages of the components are: percent of the total weight of the composition. The total mass of the soothing extracts of example 22 and comparative example 18 was 100%.
TABLE 14
Examples 23 to 25 are also provided. The soothing essence of example 23 differs from example 22 only in that: all the glucosyl glycosides are replaced by butanediol with the same mass percentage; the other components and mass percentages of the soothing essence of example 23 are the same as those of example 22. The soothing essence of example 24 differs from example 22 only in that: all the glucosyl glycosides are replaced by dipropylene glycol with the same mass percentage; the other components and mass percentages of the soothing essence of example 24 are the same as those of example 22. The soothing essence of example 25 differs from example 22 only in that: all the glucosyl glycosides are replaced by propylene glycol with the same mass percentage; the other components and mass percentages of the soothing essence of example 25 are the same as those of example 22.
The preparation method of the soothing essence of examples 22 to 25 and comparative example 18 comprises the following steps:
s1, weighing the component A2 according to a proportion, and stirring and dispersing uniformly to obtain an A2 phase;
s2, weighing the component C according to a proportion, heating to 70 ℃ at constant temperature, and stirring and dissolving completely to obtain a phase C;
s3, weighing the component D according to a proportion, heating to 80 ℃, and stirring and dissolving completely to obtain a phase D;
s4, weighing the component A according to a proportion, stirring and dissolving completely, adding the component A1 under a homogenizing condition, homogenizing and dispersing uniformly, adding the phase A2 in the step S1, homogenizing and dispersing uniformly, heating to 80 ℃ at constant temperature, preserving heat for 20min, stirring and mixing uniformly to obtain a mixed material A;
s5, cooling the mixed material A in the step S4 to 70 ℃, adding the phase B and the phase C in the step S2, and stirring and dispersing uniformly to obtain a mixed material B;
s6, cooling the mixed material B in the step S5 to 45 ℃, adding the E phase and the D phase in the step S3, and stirring and dispersing uniformly to obtain a mixed material C;
and S7, cooling the mixed material C in the step S7 to 38 ℃, and filtering and discharging through 200-mesh filter cloth to obtain the soothing essence.
Effect example 7
To further verify the skin feel of the products of the soothing cream and soothing concentrate of the present invention, the soothing concentrate sprays of examples 8, 15-17 and comparative example 14, the soothing cream of examples 18-21 and comparative example 17, and the soothing concentrate of examples 22-25 and comparative example 18 were subjected to skin feel evaluation.
The testing method comprises the following steps: under the condition of ensuring the skin safety of the testees, 20 volunteers are invited to form an evaluation group for professional experimental test. A test area of 2cm x 2cm is drawn on the inner sides of the left and right arms of the volunteers, 0.5mL of test sample (each volunteer tests all the test samples) is uniformly smeared in the arm test area, the test sample is gently massaged to be absorbed, the test sample is requested to evaluate the appearance, the fluidity and the texture before use, the spreading degree, the texture, the absorption degree, the moistening degree and the viscous feeling during use, and the soft feeling, the moisturizing degree and the viscous feeling after use, the scoring is carried out according to the scoring standard of the following table 15, and the scoring results of each group are averaged according to the scoring data in the group.
TABLE 15
| Skin feel test scoring criteria | Scoring/scoring |
| Very satisfactory | 5 |
| Satisfactory satisfaction | 4 |
| In general | 3 |
| Dissatisfaction with | 2 |
| Is very unsatisfactory | 1 |
The test results are shown in Table 16.
Table 16 units: dividing into
As can be seen from table 16, the soothing essence spray, the soothing essence cream and the soothing essence prepared from the composition with the efficacy of soothing and relieving allergy and itching according to the present invention have good skin feel.
Finally, it should be noted that the above embodiments are only for illustrating the technical solution of the present invention and not for limiting the scope of the present invention, and although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that the technical solution of the present invention may be modified or substituted equally without departing from the spirit and scope of the technical solution of the present invention.
Claims (10)
1. The composition with the effects of relaxing and anti-allergic and antipruritic is characterized by comprising the following components in parts by weight: 0.1 to 1 part of kava root extract, 0.01 to 0.5 part of olive leaf extract and 0.01 to 5 parts of black truffle extract.
2. The composition of claim 1, comprising the following components in parts by weight: 0.15 to 0.8 part of kava root extract, 0.12 to 0.3 part of olive leaf extract and 0.05 to 3 parts of black truffle extract.
3. The composition of claim 1 or 2, further comprising a humectant; the humectant is at least one selected from glycerol glucoside, glycerol, butanediol and dipropylene glycol.
4. A composition according to claim 3, wherein the humectant is a glucosyl glycoside.
5. A composition according to claim 3, wherein the humectant is present in an amount of 0.01 to 2 parts by weight.
6. The composition of claim 5, wherein the humectant is present in an amount of 0.02 to 1 part by weight.
7. Use of the composition having the efficacy of relaxing and anti-allergic and antipruritic according to any one of claims 1 to 6 in the preparation of cosmetics.
8. A cosmetic comprising the composition having the efficacy of soothing and anti-allergic and antipruritic according to any one of claims 1 to 6.
9. The cosmetic product according to claim 8, wherein the cosmetic product is in a form selected from the group consisting of a cream and/or an aqueous solution; the cream comprises a soothing essence cream, and the water agent comprises a soothing essence spray and/or a soothing essence.
10. The cosmetic according to claim 9, wherein the composition having the efficacy of soothing and anti-allergic and antipruritic is 0.12 to 8.5% by mass based on the total mass of the cosmetic.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310606411.4A CN116570542B (en) | 2023-05-26 | 2023-05-26 | Composition with effects of relaxing, relieving, resisting and relieving itching and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310606411.4A CN116570542B (en) | 2023-05-26 | 2023-05-26 | Composition with effects of relaxing, relieving, resisting and relieving itching and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116570542A true CN116570542A (en) | 2023-08-11 |
| CN116570542B CN116570542B (en) | 2023-12-15 |
Family
ID=87533868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310606411.4A Active CN116570542B (en) | 2023-05-26 | 2023-05-26 | Composition with effects of relaxing, relieving, resisting and relieving itching and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116570542B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9005674B1 (en) * | 2013-07-01 | 2015-04-14 | The Procter & Gamble Company | Method of improving the appearance of aging skin |
| CN111494266A (en) * | 2020-05-26 | 2020-08-07 | 广州雅纯化妆品制造有限公司 | Soothing and anti-allergy cosmetic composition |
| CN114948834A (en) * | 2022-07-15 | 2022-08-30 | 广州市丽泽化妆品有限公司 | Soothing and moisturizing essence and preparation method thereof |
| CN115040442A (en) * | 2022-07-25 | 2022-09-13 | 蔡阿娣 | Anti-inflammatory toning lotion containing black truffle extract fermentation product and preparation method thereof |
| US20230081296A1 (en) * | 2021-09-14 | 2023-03-16 | Nulixir Inc. | Stable non-aqueous compositions of plants extracts and methods of making the same |
-
2023
- 2023-05-26 CN CN202310606411.4A patent/CN116570542B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9005674B1 (en) * | 2013-07-01 | 2015-04-14 | The Procter & Gamble Company | Method of improving the appearance of aging skin |
| CN111494266A (en) * | 2020-05-26 | 2020-08-07 | 广州雅纯化妆品制造有限公司 | Soothing and anti-allergy cosmetic composition |
| US20230081296A1 (en) * | 2021-09-14 | 2023-03-16 | Nulixir Inc. | Stable non-aqueous compositions of plants extracts and methods of making the same |
| CN114948834A (en) * | 2022-07-15 | 2022-08-30 | 广州市丽泽化妆品有限公司 | Soothing and moisturizing essence and preparation method thereof |
| CN115040442A (en) * | 2022-07-25 | 2022-09-13 | 蔡阿娣 | Anti-inflammatory toning lotion containing black truffle extract fermentation product and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| BEARA: "《Bioguided design of new black truffle (Tuber aestivum Vittad.) product enriched with herbs and spices》", 《FOOD SCIENCE AND TECHNOLOGY》, vol. 138, pages 110637 - 2 * |
| 王海燕: "《黑松露多糖分离纯化与抗炎活性研究》", 《现代食品科技》, vol. 33, no. 8, pages 30 - 35 * |
| 素妍化妆品（北京）有限公司: "《护肤品里的活性成分添加越多，一定越好吗？》", 国家药品监督管理局, pages: 1 - 2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116570542B (en) | 2023-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112315882B (en) | Soothing, repairing and moisturizing cream and preparation method thereof | |
| WO2015024396A1 (en) | Plant composition having moisturizing, anti-wrinkle, and anti-allergic efficacies, and preparation method thereof | |
| KR20190056815A (en) | A composition for improving skin diseases containing extracts of abeliophyllum distichum and extract thereof having skin reproduction effect | |
| CN110638727A (en) | Infant hip-protecting composition and preparation method and application thereof | |
| CN112168766A (en) | Anti-inflammatory and relieving aloe gel and preparation method thereof | |
| CN111671692A (en) | Acne-removing composition and preparation method and application thereof | |
| KR100904200B1 (en) | Cosmetic composition for moisturizing the skin containing the extract of Prunella Vulgaris and Aloe Barbadensis leaf | |
| CN104188859B (en) | A kind of crease-resistant skin care emulsion containing natural component extract and preparation method thereof | |
| CN113456568A (en) | Composition for soothing, repairing and moisturizing skin and preparation method and application thereof | |
| CN116617106A (en) | Protopanaxatriol saponin allergy-relieving repairing composition, and preparation method and application thereof | |
| CN116570542B (en) | Composition with effects of relaxing, relieving, resisting and relieving itching and application thereof | |
| CN108703917B (en) | Anti-aging composition and cosmetic prepared from same | |
| CN116850081A (en) | Repairing composition for sensitive muscles, freeze-dried mask and preparation method thereof | |
| CN108721154B (en) | Skin care product for skin moisturizing and barrier repair and preparation method thereof | |
| CN113425661B (en) | Plant composition with cleaning and repairing effects and application thereof | |
| CN110279644A (en) | A kind of composition with repair of releiving and its application in cosmetics | |
| CN112807238A (en) | Anti-inflammatory and soothing repair gel for skin and preparation method thereof | |
| KR101738339B1 (en) | Composition for improving skin aging and wrinkle comprising herbal medicine mixed extract as effective component | |
| AU2020100737A4 (en) | Composition for removing striae atrophicae | |
| CN113876671A (en) | Anti-aging composition containing rape bud extract and preparation method thereof | |
| CN111096914A (en) | Hemp leaf mask for cleaning and balancing face and preparation method thereof | |
| CN115282104B (en) | Plant composite extract, anti-allergic agent, preparation method and application thereof | |
| KR102670637B1 (en) | Waxing composition for hair removal and preparation thereof | |
| KR102334349B1 (en) | Cosmetic Composition For Anti-irritation Comprising Xylooligosaccharide As Active Ingredient | |
| KR20020048211A (en) | A Composition for Protecting Human skin against dryness from eczema |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |